XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$26.42 USD
-2.02 (-7.10%)
Updated Aug 6, 2025 04:00 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XOMA 26.42 -2.02(-7.10%)
Will XOMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
What Makes XOMA Royalty (XOMA) a New Buy Stock
Other News for XOMA
I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals
XOMA Royalty Breaks Above 200-Day Moving Average - Bullish for XOMA
XOMA Royalty to acquire cancer drug developer LAVA Therapeutics
XOMA Royalty (XOMA) to Acquire HilleVax (HLVX) in Cash Deal
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1. ...